Business Paid
Biotech startups struggle to secure financing amid high interest rates
16:35
Foreign financial investors are currently showing limited interest in Polish biotechnology companies due to the high-interest rate environment, which makes other assets more attractive with faster returns, according to Tomasz Bardziłowski, managing director of Ipopema Securities.
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
